Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Quality of life changes in COPD patients treated with salmeterol.

Jones PW, Bosh TK.

Am J Respir Crit Care Med. 1997 Apr;155(4):1283-9.

PMID:
9105068
2.

Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.

Jarvis B, Markham A.

Drugs Aging. 2001;18(6):441-72. Review.

PMID:
11419918
3.

Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.

Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.

Clin Ther. 2007 Feb;29(2):261-78.

PMID:
17472819
4.

Long-acting beta2-agonists for chronic obstructive pulmonary disease.

Appleton S, Smith B, Veale A, Bara A.

Cochrane Database Syst Rev. 2000;(2):CD001104. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001104.

PMID:
10796594
5.

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.

Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S.

Thorax. 2003 May;58(5):399-404. Erratum in: Thorax. 2005 Feb;60(2):105.

6.

Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group.

Di Lorenzo G, Morici G, Drago A, Pellitteri ME, Mansueto P, Melluso M, Norrito F, Squassante L, Fasolo A.

Clin Ther. 1998 Nov-Dec;20(6):1130-48.

PMID:
9916607
7.

Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids.

Hodder R, Kesten S, Menjoge S, Viel K.

Int J Chron Obstruct Pulmon Dis. 2007;2(2):157-67.

8.

Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group.

Kemp JP, Cook DA, Incaudo GA, Corren J, Kalberg C, Emmett A, Cox FM, Rickard K.

J Allergy Clin Immunol. 1998 Feb;101(2 Pt 1):188-95.

PMID:
9500751
9.

A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.

Donohue JF, Kalberg C, Emmett A, Merchant K, Knobil K.

Treat Respir Med. 2004;3(3):173-81.

PMID:
15219176
10.

Efficacy of salmeterol xinafoate in the treatment of COPD.

Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH.

Chest. 1999 Apr;115(4):957-65.

PMID:
10208192
11.

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.

Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001104. Review.

PMID:
16855959
12.

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.

Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K.

Am J Respir Crit Care Med. 2001 Apr;163(5):1087-92.

PMID:
11316640
14.

An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)

Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C.

Eur Respir J. 1997 Apr;10(4):815-21. Erratum in: Eur Respir J 1997 Jul;10(7):1696.

15.

Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.

Pearlman DS, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, Prillaman B, Shah T.

Ann Allergy Asthma Immunol. 1999 Mar;82(3):257-65.

PMID:
10094216
16.

Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.

Cazzola M, Di Perna F, Noschese P, Vinciguerra A, Calderaro F, Girbino G, Matera MG.

Eur Respir J. 1998 Jun;11(6):1337-41.

17.

Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol.

Fukuchi Y, Nagai A, Seyama K, Nishimura M, Hirata K, Kubo K, Ichinose M, Aizawa H; Research Group TB.

Treat Respir Med. 2005;4(6):447-55.

PMID:
16336029
18.

Salmeterol reduces dyspnea and improves lung function in patients with COPD.

Ramirez-Venegas A, Ward J, Lentine T, Mahler DA.

Chest. 1997 Aug;112(2):336-40.

PMID:
9266866
20.

Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.

Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y.

Respirology. 2009 Mar;14(2):239-44. doi: 10.1111/j.1440-1843.2008.01452.x. Epub 2008 Dec 11.

PMID:
19210650

Supplemental Content

Support Center